Search Results - D. Westerman

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    P361: EARLY MEASURABLE RESIDUAL DISEASE ANALYSIS IS ONLY PREDICTIVE OF SURVIVAL OUTCOMES AFTER TWO CYCLES OF TREATMENT IN ADULTS WITH B-LYMPHOBLASTIC LEUKEMIA RECEIVING HYPER-CVAD... by R. Nedumannil, D. Ritchie, A. Bajel, A. P. Ng, S. J. Harrison, D. Westerman

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    P1306: CLINICAL AND GENOMIC ANALYSIS OF HIGH-GRADE TRANSFORMATION OF MARGINAL ZONE LYMPHOMA by C. Yannakou, D. Villa, C. Gould, Y. Kankanige, J. Lickiss, G. Ryland, S. Lade, G. Slack, W. Limvorapitak, C. Tam, J. Seymour, D. Westerman, P. Blombery

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    B02 | SONROTOCLAX AND ZANUBRUTINIB AS FRONTLINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA DEMONSTRATES HIGH MINIMAL RESIDUAL DISEASE CLEARANCE RATES WITH GOOD TOLERABILITY: DATA F... by P. Ghia, J.D. Soumerai, C.Y. Cheah, M.A. Anderson, M. Lasica, E. Verner, S.S. Opat, S. Ma, R. Weinkove, R. Cordoba, S. Leitch, D. Westerman, S. Patel, Y. Fang, W. Ding, C.S. Tam

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  4. 4

    High ovarian hormones present during fear extinction reduce fear relapse through a nigrostriatal dopamine pathway by Alyssa A. Hohorst, Margaret K. Tanner, Rebecca Han, Kamryn M. Korth, Jessica D. Westerman, Carolina Sanchez Mendoza, Miles Q. Dryden, Lareina A. Alvarez, Remla A. Abdul, Esteban C. Loetz, Erik B. Oleson, Benjamin N. Greenwood

    Published in Biology of Sex Differences (2025-06-01)
    Get full text
    Article


  5. 5

    C036 | SONROTOCLAX (SONRO; BGB-11417), A NOVEL BCL2 INHIBITOR, PLUS ZANUBRUTINIB DEMONSTRATES DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY CLL/SLL: UPDATED PHASE-1 RESULTS by A. Tedeschi, C.Y. Cheah, C.S. Tam, M.A. anderson, E. Verner, M. Lasica, A. Arbelaez, S. Stilgenbauer, P. Browett, S. Leitch, E. González-Barca, M. Shadman, J-Z. Hou, H. Eradat, D. Westerman, Y. Fang, J. Hilger, S. Patel, S.S. Opat

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  6. 6

    P776: A PHASE 2, OPEN-LABEL, ASCENDING DOSE STUDY OF KER-050 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES by S. Tan, A. Arbelaez, L. Chee, C. Y. Fong, D. Hiwase, G. Kannourakis, J. Kwan, J. Liang, A. Puliyayil, H. Rose, D. Ross, T.-C. Teh, D. Westerman, J. Wight, W. Feng, J. Lachey, A. McGinty, H. Natarajan, C. Rovaldi, S. Cooper

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: